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We studied the in vitro effects of sex hormones on
vascular endothelial growth factor (VEGF) produc-
tion in differentiated THP-1 monocytic cells.
Phorbol-12-myristate-13-acetate differentiated THP-
1 into macrophage-like cells. 17b-estradiol (10±9 M)
increased VEGF secretion of controls 3.1-fold in dif-
ferentiated THP-1 and this effect of 17b-estradiol
was antagonized by dihydrotestosterone, although
dihydrotestosterone alone did not alter VEGF secre-
tion. 17b-estradiol increased steady-state mRNA
level of VEGF and the increase was counteracted
by dihydrotestosterone in differentiated THP-1,
although dihydrotestosterone alone did not alter the
VEGF mRNA level. Progesterone did not affect the
constitutive and 17b-estradiol-induced VEGF secre-
tion and mRNA level. Transient transfection
revealed that 17b-estradiol enhanced chlorampheni-
col acetyl transferase expression driven by VEGF
promoter and the enhancement was antagonized by
dihydrotestosterone. Adenylate cyclase inhibitor sup-
pressed 17b-estradiol-induced enhancement of VEGF
secretion, mRNA level, and promoter activity,
whereas dihydrotestosterone-induced suppression on
the effects of 17b-estradiol was counteracted by 3¢,5¢-
adenosine cyclic monophosphate (cAMP) analog.
17b-estradiol increased intracellular cAMP level by
activating adenylate cyclase, while dihydrotesto-
sterone reduced the basal and 17b-estradiol-increased
cAMP level by inhibiting adenylate cyclase.
Transfection with 5¢-deleted VEGF promoters
demonstrated that the region between ±88 and
±66 bp may be involved in the transcriptional regula-
tion by each hormone. The mutation within activa-
tor protein-2 element in this region abrogated the
transcriptional stimulation and repression by the
respective hormones. 17b-estradiol activated tran-
scription from activator protein-2-responsive repor-
ter plasmid while dihydrotestosterone antagonized
the effect of 17b-estradiol. These results suggest that
17b-estradiol enhances VEGF production while
dihydrotestosterone antagonizes the effect of 17b-
estradiol via up- or downregulation of adenylate
cyclase in differentiated THP-1. Key words: AP-2/
cAMP/lobular capillary hemangioma. J Invest Dermatol
118:519±529, 2002
T
he lobular capillary hemangioma (LCH) typically
occurs as a red nodule in the skin or mucous
membrane, and is histologically composed of pro-
liferating endothelial cells that are sometimes seen in a
lobular pattern and accompanied by a mixed in¯am-
matory cell in®ltrate (Nichols et al, 1992). It is known that LCH
frequently occurs or rapidly enlarges during pregnancy (Nichols
et al, 1992). The pregnancy-associated LCH often regress after
delivery (Nichols et al, 1992). LCH is also associated with the use of
oral contraceptives (Nichols et al, 1992). These clinical features
suggest that the development of LCH may involve sex hormones,
especially estrogen and/or progesterone (P) whose levels increase
during pregnancy. The vascular proliferation requires certain
growth factors for endothelial cells (Yuan et al, 2000). Previous
studies suggest that the pathogenesis of LCH may be mediated by
the enhanced production of vascular endothelial cell growth factor
(VEGF) in stromal cells like macrophages (Yuan et al, 2000). It is
thus hypothesized that estrogen or P may enhance VEGF
production by macrophages. Previous studies also reported that
estrogen in vivo and in vitro enhanced VEGF production in rat
uterus (Cullian-Bove and Koos, 1993; Hyder et al, 1996) or
pituitary (Ochoa et al, 2000) or human endometrial cells (Shifren
et al, 1996). P also enhanced VEGF production in rat uterus
(Cullian-Bove and Koos, 1993) or bovine retinal pigment epithelial
cells (Sone et al, 1996). Male hormone dihydrotestosterone (DHT)
is also reported to increase VEGF production in human prostate
cancer cells (Joseph et al, 1997); however, the precise mechanism
for the regulation of VEGF production by sex hormones is
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unknown. It is known that steroid hormones manifest their effects
by two different mechanisms, genomic effects and nongenomic
effects. The former is that classical nuclear receptor binds to the
respective hormone and this hormone-receptor complex activates
the transcription of various genes (Beato, 1989). On the other
hand, in the latter case, steroid hormones rapidly up- or down-
regulate a variety of intracellular signals; estrogen activates adenylate
cyclase (Aronica et al, 1994), protein kinase C (Ansonoff and Etgen,
1998), or extracellular signal-regulated kinases (Migliaccio et al,
1996). The recent studies reported the presence of membrane
steroid receptors that mediate rapid nongenomic steroid actions
(Papas et al, 1995). As above-mentioned signaling molecules are
required for the expression of certain genes, the nongenomic
signal-modulating effects of sex hormones may also lead to the up-
or downregulation of certain gene expression.
In this study, we examined the in vitro effects of 17b-estradiol
(E2), P, and DHT on VEGF production in phorbol-12-myristate-
13-acetate (PMA)-differentiated human monocytic THP-1 cells.
These cells are a suitable model for tissue macrophages as PMA
differentiates THP-1 into mature macrophages with enhanced
adherence or phagocytosis (Grif®n et al, 1989). We found that E2
enhanced VEGF production whereas DHT antagonized the
enhancement by E2 in differentiated THP-1. We further examined
the mechanism for the effects of these hormones focusing on the
signaling events involved in VEGF production.
MATERIALS AND METHODS
Reagents E2, 17a-estradiol, P, DHT, b-dihydrotestosterone, and
PMA were purchased from Sigma (St. Louis, MO). SQ22536, PD
98059, calphostin C, 1-oleoyl-2-acetyl-sn-glycerol (OAG), C8 ceramide,
and dibutyryl 3¢,5¢-adenosine cyclic monophosphate (Bt2cAMP) were
from Calbiochem-Novabiochem (San Diego, CA). Cyproterone acetate
was from Schering (Berlin, Germany) and ICI 182 780 was from Zeneca
(Maccles®eld, U.K.). These reagents were dissolved at 100 mM in
dimethyl sulfoxide and were kept in the dark until used. Mouse IgG
monoclonal antihuman VEGF antibody was from R&D Systems
(Minneapolis, MN). Control mouse IgG was from Dako (Carpinteria,
CA).
Differentiation of THP-1 cells Human monocytic THP-1 cells were
purchased from Dainippon Pharmaceutical (Osaka, Japan) and were
cultured in RPMI 1640 (Gibco-BRL, Grand Island, NY) supplemented
with 10% heat-inactivated fetal calf serum (Gibco-BRL) supplemented
with 100 U penicillin G per ml, 100 mg streptomycin per ml, 0.25 mg
amphotericin B per ml (Gibco-BRL). For differentiation, cells were
plated at 2 3 105 cells per ml in medium containing 100 nM PMA and
allowed to attach for 48 h as described (Bienkowski et al, 1989). The
cells were then fed with PMA-free medium and cultured overnight prior
to use. PMA-induced differentiation altered the morphology of THP-1
from nonadherent to adherent cells.
Measurement of cytokines To measure the secretion of cytokines,
PMA-differentiated THP-1 cells were trypsinized, washed three times
with phosphate-buffered saline, then plated in triplicate at 1 3 105 per
well in 24-well plates, adhered for 8 h in phenol red-free M199 medium
(Gibco-BRL) supplemented with 5% heat-inactivated fetal calf serum,
then washed and incubated with sex hormones in 1 ml per well of
phenol red-free, serum-free M199 medium containing various
concentrations of sex hormones for 24 h. Control cells were incubated
in medium alone. The conditioned media were removed and the
amount of VEGF in the media was measured by an enzyme-linked
immunosorbent assay (ELISA) kit from Biosource (Cammarilo, CA)
according to the manufacturers' instruction. The sensitivity of the assay
was 5 pg per ml, respectively.
For the analysis of cytokine mRNA levels, reverse transcription (RT)-
polymerase chain reaction (PCR) was performed as described (Kanda,
1999). Differentiated THP-1 cells were incubated with sex hormones as
above for 6 h, and were harvested by trypsinization. Total RNA was
extracted from the harvested cells, and was reverse-transcribed as
described (Kanda, 1999). PCR conditions are described elsewhere
(Kanda, 1999). The VEGF primers were 5¢-GAC CAC CTG CCT
CCT GAC ACT TC-3¢ and 5¢-TCT CAG CCC TCT TCA AAA
ACT TCT C-3¢ (Brown et al, 1997), and PCR products of 171-bp,
303 bp, and 375 bp corresponded to splicing variants VEGF121,
VEGF165, and VEGF189, respectively. b-actin primers were 5¢-GAG
TGT GTG CCC ACT GAG GAG TC-3¢ and 5¢-GGT CTC AAA
CAT GAT CTG GG-3¢ (PCR product size 268 bp) (Kanda, 1999). The
PCR products were analyzed by electrophoresis on 2.5% agarose gels
and stained with ethidium bromide. The band intensity of the PCR
products for VEGF was determined by densitometry (Hoefer Scienti®c
Instruments, San Fransisco, CA) and the ratio relative to b-actin product
was calculated.
Plasmids, transfection, and chloramphenycol acetyl transferase
(CAT) assay The different VEGF-CAT constructs were generated by
inserting the corresponding VEGF promoter sequences into pCAT3
basic vector (Promega, Madison, WI). The KpnI-NheI fragment of the
genomic VEGF DNA, which spans nucleotides ±856 to +54 bp relative
to the transcriptional start site (Tischer et al, 1991), was subcloned into
pCAT3 basic vector as described (Maity et al, 2000). Construct ±88/+54
was obtained by cutting the above vector by SmaI (one site in the vector
and one site at position ±88 of the promoter) and re-ligating. The
construct ±66/+54 was generated by PCR using a forward primer 5¢-
GCGGGTACCTCCCGGCGGGGCGG-3¢ and a reverse primer 5¢-
CTTTATGTTTTTGGCGTCTTCCA-3¢ as described (Milanimi et al,
1998). The ampli®ed fragments were digested with KpnI and NheI, and
inserted into the pCAT3 basic vector. We mutated the AP-2 site (±79 to
±71) by PCR method as described (Ho et al, 1989; Gille et al, 1997;
Milanimi et al, 1998; Shi et al, 2001) by using primers 5¢-GGG-
GCGGGCC(TA)GGGCGGGG-3¢ and 5¢-CCCCGCCC(TA)GGC-
CCGCCCC-3¢, where bases shown in brackets indicate those modi®ed
in relation to the wild-type sequence. After obtention of the ±856/+54
mutated constructs, we digested them with SmaI to obtain the
corresponding ±88/+54 constructs. The presence of the mutation was
con®rmed by gel sequencing using the Sequenase Quick-Denature
Plasmid Sequencing Kit (Amersham, Arlington Heights, IL). p3x AP-2-
tk-CAT was constructed by inserting three copies of the sequence 5¢-
CTGAC CGCCC GCGGC CCGT-3¢, corresponding to nucleotides
±185 to ±167 bp of the human metallothionein IIa gene distal basal level
element, in front of minimal thymidine kinase promoter (±109 to
+51 bp) upstream of CAT reporter (Williams et al, 1988). Transfection
of PMA-differentiated THP-1 cells was carried out by electroporation as
described (Mueller et al, 2000). Brie¯y, a total of 1.4 3 107 differentiated
THP-1 cells were transfected with 30 mg of wild-type or mutant VEGF-
CAT or p3x AP-2-tk-CAT by electroporation at 300 V and 960 mF in
700 ml of Dulbecco's phosphate-buffered saline, using a Bio-Rad Gene
Pulser. The cells were subdivided into 24-well plates at 5 3 104 cells per
well and incubated for 24 h in 1 ml per well of phenol red-free M199
medium supplemented with 5% fetal calf serum. This procedure
eliminates differences in transfection ef®ciency since the same construct is
used for the transfection of separate cultures. Then the medium was
discarded and the cells were washed with phosphate-buffered saline, and
incubated with sex hormones at the indicated concentrations in 1 ml per
well of serum-free, phenol red-free M199 medium. After 18 h, the cells
were harvested and lyzed by three freeze/thaw cycles. The cell lysate was
centrifuged and supernatant was assayed for CAT expression by CAT-
ELISA (Roche Diagnostics, Tokyo, Japan) according to the
manufacturer's instruction. Total protein amount was measured by a
Bio-Rad protein assay kit. The expression of various CAT plasmids was
presented as pg CAT enzyme synthesized per mg total protein. pCAT3-
control vector (Promega) containing SV40 early promoter and enhancer
sequences was used as a positive control, and promoterless pCAT3-basic
vector was used as a negative control.
Measurement of cAMP amount PMA-differentiated THP-1 cells
were plated at 5 3 104 cells per well in 24-well plates, adhered for 8 h,
washed, and incubated with indicated concentrations of sex hormones in
1 ml per well of serum-free, phenol red-free M199 medium for the
indicated duration. The medium was discarded, and the cells were lyzed
with acetate buffer (pH 5.8) containing 0.25% dodecyltrimethyl-
ammonium bromide. The cAMP amount in the lysate was measured
with an ELISA kit from Amersham (Arlington Heights, IL) according to
the manufacturer's instruction. The sensitivity of the assay was 12 fmol
per assay well. The intracellular cAMP level was presented as pmol per
106 cells.
Measurement of PDE activity PMA-differentiated THP-1 cells were
cultured with sex hormones for 5 min in 24-well plates as described
above, and were lyzed in the buffer containing 20 mM Tris-HCl
(pH 7.4), 1 mM EDTA, 1 mg aprotinin per ml, 1 mg pepstatin per ml,
1 mg leupeptin per ml, 15 mM benzamidine, and 3.75 mM b-
mercaptoethanol. PDE activity of the cell lysate was assayed as described
(Epstein et al, 1980; Robicsek et al, 1991) using 1 mM [2,8±[3H]] cAMP
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(30 Ci per mmol) (Amersham) as a substrate. The assays were performed
in 40 mM Tris-HCl (®nal pH 8.0), 10 mM MgCl2 at 37°C for 10 min,
and PDE activity was presented as pmol cAMP hydrolyzed per min per
mg protein.
Measurement of AC activity The above-mentioned lysate of
differentiated THP-1 cells was centrifuged at 23 600 3 g for 10 min.
The pellet was used as a particulate fraction for AC assays as described
(Salomon et al, 1974; Choi et al, 1992). The AC activity of the fraction
was measured at 37°C for 10 min in 20 mM Tris-HCl (pH 7.4), 1 mM
[a-32P] ATP (30 Ci per mmol) (Amersham), 1 mM [[3H]] cAMP,
1 mM 3-isobutyl-1-methylxanthine, 5 mM MgCl2, 0.2 mM EGTA,
20 mM creatine phosphate, and 100 units creatine phosphokinase per ml.
AC activity was presented as pmol cAMP formed per min per mg
protein.
Endothelial cell proliferation assay Human dermal microvascular
endothelial cells (Cell Systems, Kirkland, WA) were maintained in CS-C
complete serum-free medium (Cell Systems), including human serum
albumin, human lipoproteins, acidic ®broblast growth factor, and
epidermal growth factor. The endothelial cells were plated at 5 3 103
cells per well in triplicate in laminin-coated 96-well plates in 100 ml of
complete medium and adhered for 8 h. The medium was discarded and
the plates were washed with phosphate-buffered saline three times, then
100 ml of the medium conditioned by differentiated THP-1 was added
to the endothelial cells, and left for 18 h. Then 0.5 mCi per well of
[3H]-thymidine (Amersham) was added and the cells were incubated for
additional 6 h prior to harvest. The incorporation of [3H]-thymidine was
assayed by liquid scintillation.
The endothelial cells were plated at 1 3 104 cells per well in triplicate
in laminin-coated 24-well plates in 1 ml of complete medium and
adhered for 8 h. The medium was discarded and the plates were washed
with phosphate-buffered saline three times, then 1 ml of the medium
conditioned by differentiated THP-1 was added to the endothelial cells,
and cultured. The cells were harvested and counted for ®ve consecutive
days. Results were expressed as the mean number of cells per well 6
SEM.
Statistical analyzes One-way analysis of variance with Dunnet's
multiple comparison test was used for the data in Figs 1(a) and 2(b).
One-way analysis of variance with Scheffe's multiple comparison test was
used for the data in Figs 1(b), 2(a, c), 4, 5(a, b), 6(a, b), 7(b, c), 8, 9,
and 10.
RESULTS
The effects of E2, P, and DHT on VEGF secretion in
differentiated THP-1 cells VEGF is constitutively produced by
differentiated THP-1 cells (495.6 6 51.2 pg by 1 3 105 cells). E2
concentration-dependently enhanced the VEGF secretion; 3.1-fold
increase by 10±9 M of E2 compared with controls (Fig 1a). E2
stereoisomer 17a-estradiol, known to be biologically inactive as an
estrogen, did not alter VEGF secretion. P did not alter VEGF
secretion at concentrations from 10±12 to 10±6 M. DHT appeared
to slightly reduce VEGF secretion (by 10% of controls at 10±8 M);
however, that was not statistically signi®cant. The E2-induced
increase of VEGF secretion was not blocked by nuclear estrogen
receptor antagonist ICI 182 780 (Fig 1b). Though DHT did not
alter the constitutive VEGF secretion, it concentration-
dependently suppressed the E2-induced increase of VEGF
secretion, and at 10±8 M, completely abrogated the E2-induced
increase (Fig 1b). The E2-antagonizing effect of DHT was not
blocked by nuclear androgen receptor antagonist cyproterone
acetate. DHT stereoisomer b-dihydrotestosterone and P did not
affect the E2-induced increase of VEGF secretion (data not shown).
Thus E2 enhanced VEGF secretion in differentiated THP-1 and
DHT antagonized the enhancement by E2, and these effects did
not appear to be mediated by classical nuclear receptors for the
respective steroids.
VEGF-dependent growth-promotion on endothelial cells by
conditioned medium from differentiated THP-1 We then
examined if the media conditioned by differentiated THP-1 may
enhance the endothelial cell proliferation. Conditioned medium
from E2-incubated THP-1 signi®cantly enhanced [3H]-thymidine
uptake of human dermal microvascular endothelial cells by 3.5-fold
compared with the control conditioned medium from the same
cells incubated with medium alone (Fig 2a). The growth-
promoting effect of conditioned medium from P or DHT-treated
THP-1 was comparable with that of the control conditioned
medium. DHT reduced the growth-promoting effect of E2-
conditioned medium to the control level, which paralleled the
inhibition of E2-induced VEGF secretion by DHT (Fig 1b). The
direct addition of E2, DHT, or P to the culture of endothelial cells
did not alter [3H]-thymidine uptake of these cells, indicating that
these hormones may not directly alter their growth. Anti-VEGF
antibody concentration-dependently inhibited the growth-
promoting effects of both control and E2-conditioned media
(Fig 2b). These results indicate that VEGF may act as a major
growth factor for endothelial cells. It is also indicated that E2 may
enhance DNA synthesis of endothelial cells cultured with
Figure 1. The inhibitory effects of sex hormones on VEGF
secretion. (a) PMA-differentiated THP-1 cells were incubated with E2,
17a-estradiol, P, or DHT at the indicated concentrations for 24 h and
VEGF concentration in the supernatants was analyzed by ELISA. Results
represent the mean 6 SEM of four separate experiments. *p < 0.05
versus control cultures with medium alone, by one-way analysis of
variance with Dunnet's multiple comparison test. (b) The cells were
incubated with the indicated combination of E2 (10±9 M), DHT (10±10,
10±9, or 10±8 M), ICI 182 780 (ICI; 10±6 M), or cyproterone acetate
(CYP; 10±6 M), and VEGF secretion was analyzed. The data are shown
as percent versus VEGF secretion in control cultures with medium alone.
Results represent the mean 6 SEM of four separate experiments.
*p < 0.05 versus control cultures with medium alone, and ²p < 0.05
versus cultures with E2 alone, by one-way analysis of variance with
Scheffe's multiple comparison test. The VEGF secretion in control
cultures was 495.6 6 51.2 pg per ml (mean 6 SEM, n = 4).
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conditioned medium from differentiated THP-1 indirectly by
increasing VEGF secretion in THP-1, and that DHT may
antagonize the effect of E2 by inhibiting the E2-induced increase
of VEGF secretion.
When the growth of endothelial cells was analyzed by direct cell
counting, conditioned medium from E2-incubated THP-1 also
increased the cell number over a 5-d period more potently than the
control conditioned medium; 2.8-fold of the cell number cultured
with control conditioned medium on day 5 (Fig 2c). DHT
reduced the growth-promoting effect of E2-conditioned medium
to the level of control conditioned medium, which paralleled the
results in [3H]-thymidine uptake.
The effects of E2, P, and DHT on VEGF mRNA levels in
differentiated THP-1 cells We then analyzed if the steady-state
mRNA level of VEGF in differentiated THP-1 may be altered by
E2, P, or DHT. As analyzed by RT-PCR, the bands corresponding
to VEGF121 and VEGF165 splicing variants are constitutively
expressed in PMA-differentiated THP-1, and the intensity for
VEGF121 was higher; the intensity ratio of VEGF121/VEGF165 was
1.82 (Fig 3). Both the mRNA levels for VEGF121 and VEGF165
were enhanced by E2 but unaltered by P or DHT; however, DHT
suppressed the E2-induced increase of VEGF121 and VEGF165
mRNA levels. These results indicate the pretranslational
stimulation or suppression by E2 or DHT, respectively. ICI
182 780 did not block the E2-induced increase of VEGF121 and
VEGF165 mRNA levels, and cyproterone acetate did not block the
suppressive effect of DHT on E2, which paralleled the results in
VEGF secretion (Fig 1b). The intensity ratio of VEGF121/
VEGF165 was not altered by either steroid alone or in
combination, which was always 1.8±1.9. No distinct bands
corresponding to VEGF189 were present, either in the presence
or in the absence of steroids (data not shown). We then examined if
E2 and DHT may exert their effects at the transcriptional level by
analyzing the effects of these hormones on the activity of VEGF
promoter.
The effects of E2, P, and DHT on VEGF promoter
activity PMA-differentiated THP-1 cells were transiently
transfected with plasmid containing a full-length VEGF promoter
(±856/+54) driving CAT reporter gene, and the promoter activity
was assessed by the expression of CAT enzyme. As shown in Fig 4,
the activity of VEGF promoter in differentiated THP-1 cells was
enhanced 3.6-fold by E2, unaltered by P or DHT, whereas DHT
counteracted the E2-induced increase of VEGF promoter activity.
ICI 182 780 or cyproterone acetate did not abolish the E2-induced
stimulation of VEGF promoter activity or DHT-induced
suppression on the effect of E2, respectively. These results suggest
that E2 may enhance VEGF production while DHT may
antagonize the enhancement by E2 both at the transcriptional
level, respectively, though post-transcriptional regulation is also
possible.
The involvement of cAMP in E2-induced stimulation of
VEGF production and in DHT-induced antagonism on the
effect of E2 Because antagonists of nuclear estrogen or androgen
receptor did not abolish the up- or downregulation of VEGF
production, respectively, the effects of E2 and DHT may not
involve classical nuclear receptors, but may be mediated by
modulating certain signaling pathways involved in VEGF
production. It is known that E2 activates adenylate cyclase
(Aronica et al, 1994), protein kinase C (Ansonoff and Etgen,
1998), or extracellular signal-regulated kinases (Migliaccio et al,
1996), and these signaling molecules are involved in VEGF
transcription (Garrido and Saule, 1993; Hoper et al, 1997; Milanimi
et al, 1998), indicating that E2-induced stimulation of VEGF
production may involve either of these signals. We thus examined
if the inhibitors for these signaling molecules may abrogate the E2-
induced stimulation of VEGF production. As shown in Fig 5,
adenylate cyclase inhibitor SQ 22536 suppressed the E2-induced
enhancement of VEGF secretion (Fig 5a), promoter activity
(Fig 5b), and mRNA level (Fig 5c), and the suppression by SQ
22536 was reversed by cAMP analog Bt2cAMP. On the other
hand, protein kinase C inhibitor calphostin C or PD 98059 that
inhibits the activation of extracellular signal-regulated kinases, did
Figure 2. The effects of media conditioned by differentiated
THP-1 on the proliferation of endothelial cells. (a) [3H]-thymidine
uptake was determined in human dermal microvascular endothelial cells
exposed to media conditioned by differentiated THP-1 cultured with
medium alone (denoted as control CM), or E2 10±9 M (E2-CM), P 10±9
M (p-CM), DHT 10±8 M (DHT-CM), or E2 plus DHT (E2 + DHT-
CM). In parallel experiments, the sex hormones were directly added to
endothelial cells at the onset of culture with control CM (control
CM + P, DHT, E2 or E2 + DHT). The data are shown as percent
versus [3H]-thymidine uptake in endothelial cell cultures with control
CM. Results represent the mean 6 SEM of four separate experiments.
[3H]-thymidine uptake in cultures with control CM was 11 376 6 1035
cpm (mean 6 SEM, n = 4). *p < 0.05 versus cultures with control CM,
and ²p < 0.05 versus cultures with E2-CM, by one-way analysis of
variance with Scheffe's multiple comparison test. (b) The anti-VEGF
antibody or control mouse IgG was added to the endothelial cell culture
with control CM or E2-CM at the indicated concentrations and [3H]-
thymidine uptake was analyzed. The data are shown as percent versus
[3H]-thymidine uptake in endothelial cell cultures with control CM.
Results represent the mean 6 SEM of four separate experiments. [3H]-
thymidine uptake in cultures with control CM was 12 176 6 1106 cpm
(mean 6 SEM, n = 4). *p < 0.05 versus cultures with E2-CM alone, and
²p < 0.05 versus cultures with control CM alone, by one-way analysis of
variance with Dunnet's multiple comparison test. (c) The endothelial cells
were cultured with control CM, E2-CM, P-CM, DHT-CM, or
E2 + DHT-CM for 5 d. On each day, the cultures were harvested, and
the number of cells present was quanti®ed. Results represent the mean
6 SEM of four separate experiments. *p < 0.05 versus cultures with
control CM on each day, and ²p < 0.05 versus cultures with E2-CM, by
one-way analysis of variance with Scheffe's multiple comparison test.
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not abolish the E2-induced enhancement of VEGF production.
These results suggest that adenylate cyclase and its end-product
cAMP may mediate the E2-induced stimulation of VEGF
production.
We then examined if activators for the above-mentioned
signaling molecules may counteract the DHT-induced inhibition
on the enhancement of VEGF production by E2. cAMP analog
Bt2cAMP abrogated the DHT-induced inhibition of the E2 effects
on VEGF secretion (Fig 6a), promoter activity (Fig 6b), and
mRNA level (Fig 6c), while PKC activator OAG or C8 ceramide,
which activates extracellular signal-regulated kinases (Galve-
Roperh et al, 1997), did not abrogate the DHT-induced inhibition
of the E2 effects on VEGF production. These results suggest that
cAMP may be involved in the DHT-induced inhibition on the E2-
enhanced VEGF production.
The effects of E2 and DHT on intracellular cAMP level, AC
and PDE activities in differentiated THP-1 We then
examined if E2 or DHT may alter cAMP level in differentiated
THP-1 cells. E2 rapidly (5 min) increased intracellular cAMP up to
5-fold of basal level, which was followed by gradual decrease and
recovery to the basal level at 3 h (Fig 7a). P did not alter cAMP
level in differentiated THP-1. DHT alone decreased cAMP
concentration by 50% of basal level at 1 h. DHT also inhibited
the cAMP elevation induced by E2; 87% inhibition of the E2-
induced increase of cAMP at 5 min. E2 stereoisomer 17a-estradiol
or DHT stereoisomer b-dihydrotestosterone did not alter cAMP
level, and ICI 182 780 or cyproterone acetate did not antagonize
the E2-induced increase or DHT-induced decrease of cAMP level,
respectively (data not shown). Thus E2 elevated the intracellular
cAMP level while DHT decreased the basal and E2-increased the
cAMP level in differentiated THP-1. We then examined if these
steroids may stimulate or inhibit the activity of AC, cAMP-
synthesizing enzyme. E2 increased AC activity 3.1-fold of controls
(Fig 7b), whereas DHT alone decreased AC activity by 70% of
controls and almost completely abrogated the E2-induced increase
of AC activity. P, 17a-estradiol, or b-dihydotestosterone (data not
shown) did not alter AC activity and ICI 182 780 or cyproterone
acetate did not antagonize the E2-induced increase or DHT-
induced decrease of AC activity (data not shown). Because the
alteration of cAMP level is also mediated by the activation or
inhibition of PDE, which hydrolyzes cAMP, we examined if these
steroids may up- or downregulate PDE activity. E2, P, DHT, or E2
plus DHT did not alter PDE activity (Fig 7c). These results suggest
Figure 3. RT-PCR analysis for the effects of
sex hormones on steady-state VEGF mRNA
level in differentiated THP-1. PMA-
differentiated THP-1 cells were cultured with the
indicated combination of E2 (10±9 M), P (10±9
M), DHT (10±8 M), ICI 182780 (ICI; 10±6 M),
cyproterone acetate (CYP; 10±6 M). After 6 h,
RNA was extracted from the harvested cells, and
RT-PCR was performed. RT-PCR products
were analyzed by electrophoresis (a) and the
intensity of the products was analyzed by
densitometry (b, c). The data represent four
separate experiments.
Figure 4. The effects of sex hormones on VEGF promoter
activity in differentiated THP-1. PMA-differentiated THP-1 cells
were transfected with VEGF promoter (±856 to +54 bp)-CAT reporter
construct and cultured with indicated combinations of E2 (10±9 M), P
(10±9 M), DHT (10±8 M), ICI 182780 (ICI; 10±6 M), or cyproterone
acetate (CYP; 10±6 M). The VEGF promoter activity was assessed by
CAT expression of the cell lysate. The data are shown as percent versus
CAT expression in control cultures with medium alone. Results
represent the mean 6 SEM of four separate experiments. *p < 0.05
versus control cultures, and ²p < 0.05 versus cultures with E2 alone, by
one-way analysis of variance with Scheffe's multiple comparison test.
The CAT expression in control cultures was mean 6 SEM (n = 4)
60.5 6 5.8 pg CAT per mg protein. The CAT expression in pCAT3-
control vector was 145.5 6 13.6 pg CAT per mg protein. The CAT
expression by promoterless pCAT3-basic vector was less than detectable
level.
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that E2 or DHT increased or decreased intracellular cAMP level in
differentiated THP-1 cells by stimulating or inhibiting AC activity,
respectively. It is also indicated that E2-induced increase of cAMP
may promote the VEGF transcription, whereas DHT may
antagonize the E2-induced VEGF transcription by inhibiting the
E2-induced increase of cAMP.
The effects of E2 and DHT on the transcriptional activation
via AP-2 To characterize the DNA sequences involved in
cAMP-induced activation of VEGF transcription, we used CAT
expression plasmids linked to serially 5¢-deleted VEGF promoters,
and compared the effects of sex hormones on the activities of the
deleted promoters. The basal promoter activity of ±856/+54 CAT
was increased by E2 (Fig 8). The basal promoter activity of ±88/
+54 CAT was almost comparable with that of ±856/+54 CAT, and
E2 increased the activity of this shorter promoter to an extent
similar to that in ±856/+54 CAT; however, when the cells were
transfected with ±66/+54 CAT, the basal and E2-induced
transcriptional activities were mostly lost. DHT-induced
repression of E2-enhanced promoter activity was revealed in
±856/+54 CAT and ±88/+54 CAT was not obtained in ±66/+54
CAT. These ®ndings indicate that critical gene regulatory elements
necessary for the constitutive and E2-induced expression are
located between bp ±88 and ±66 of the VEGF promoter, and that
this region may also be required for the repression by DHT on E2-
induced VEGF transcription. This region bp ±88 and ±66 contains
AP-2 element (±79 to ±71; 5¢-GCCGGGGGC-3¢) (Gille et al,
1997). It is reported that cAMP-dependent protein kinase, protein
kinase A enhances the transcriptional activity of AP-2 via
phosphorylation (Imagawa et al, 1987; Garcia et al, 1999).
Previous studies also suggest that transcription factor AP-2 may
mediate the induction of VEGF transcription by cAMP-elevating
agents (Hoper et al, 1997). We thus examined if the AP-2 element
(±79 to ±71) may confer the E2- or DHT-induced up- or
downregulation of VEGF transcription by using the promoter with
mutation in this element. E2 increased the activity of wild-type
VEGF promoter (±88/+54) 3.73-fold of controls, and AC inhibitor
SQ22536 abrogated the E2-induced increase (Fig 9), indicating
the involvement of AC and cAMP in the effect of E2. DHT also
inhibited the E2-induced increase of wild-type promoter activity
by 95%. The mutation of AP-2 element reduced the constitutive
promoter activity by 30%, indicating that this AP-2 element may
partially confer the constitutive promoter activity. The mutation of
this AP-2 element abrogated the E2-induced upregulation of
promoter activity; E2-induced increase of AP-2-mutated promoter
activity was 1.12-fold versus controls. The mutation of AP-2
element also abrogated the DHT-induced inhibition of E2-
enhanced promoter activity. These results suggest that the AP-2
element (±79 to ±71) may confer the E2-induced VEGF
transcription and the DHT-induced antagonism of the effect of
E2 via cAMP.
We also examined if E2 and DHT may alter the enhancer
activity of AP-2. PMA-differentiated THP-1 cells were transfected
with the plasmid containing three repeats of AP-2 from the human
metallothionein IIa gene, upstream of the minimal thymidine
kinase promoter and CAT reporter (p3xAP-2-tk-CAT). The
transcription from the AP-2-responsive reporter plasmid was
stimulated by E2 by 5.2-fold of controls, and the E2-induced
increase was abrogated by SQ22536 (Fig 10). DHT inhibited the
constitutive transcription from the AP-2-responsive reporter
plasmid by 30% and also inhibited the E2-induced increase of the
transcription by 97%. When the cells were transfected with tk-
CAT without AP-2 sequences, E2, DHT, or E2 plus DHT did not
Figure 5. The effects of signaling enzyme
inhibitors on the E2-induced stimulation on
VEGF secretion, promoter activity, and
mRNA level in differentiated THP-1. (a)
PMA-differentiated THP-1 cells were pre-
incubated for 30 min with or without SQ22536
10±4 M, SQ22536 plus Bt2cAMP 10
±4 M,
PD98059 10±5 M, or calphostin C (CalC) 10±7
M, then E2 was added to the culture at 10±9 M
®nally, and the cells were cultured for 24 h in the
presence or absence of above-mentioned agents.
VEGF secretion was analyzed by ELISA. (b)
Differentiated THP-1 cells were transfected with
VEGF promoter (±856 to +54 bp)-CAT reporter.
After 24 h, the transfected cells were preincubated
with indicated agents as above, then incubated
with E2 10±9 M in the presence or absence of
respective agents. After 18 h, VEGF promoter
activity was assayed by CAT expression of the cell
lysate. The data are shown as percent versus the
values in control cultures with medium alone, and
represent the mean 6 SEM of four separate
experiments. The control VEGF secretion was
501.5 6 49.6 pg per ml and the control VEGF
promoter activity was 59.6 6 5.4 pg CAT per mg
protein (mean 6 SEM, n = 4). The CAT
expression in pCAT3-control vector was 146.7 6
14.5 pg CAT per mg protein. The CAT
expression by promoterless pCAT3-basic vector
was less than detectable level. *p < 0.05 versus
control cultures with medium alone, and
²p < 0.05 versus cultures with E2 alone, by one-
way analysis of variance with Scheffe's multiple
comparison test. (c) The cells were preincubated
with indicated agents, and incubated with E2 as
described above. After 6 h, RNA was extracted
and RT-PCR products were analyzed by
electrophoresis. The data represent four separate
experiments.
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alter CAT expression driven by this plasmid, indicating the speci®c
effects of E2 and DHT on AP-2 sequences. These results suggest
that E2 or DHT may enhance or suppress the enhancer activity of
AP-2 via cAMP, respectively.
DISCUSSION
This study demonstrated that E2 enhanced VEGF production while
DHT antagonized the enhancement by E2 in PMA-differentiated
THP-1 cells via up- or downregulation of AC, respectively. The
enhancement of VEGF production by E2 and its antagonism by
DHT occurred at the transcriptional level via AP-2 element (±79 to
±71 bp). Our results mostly agree with those of Aronica et al
(1994); E2 enhanced AC activity and thus induced the gene
transcription from the cAMP-response element in their study;
however, consensus cAMP-response element is not present on
VEGF promoter, and cAMP-induced VEGF transcription appears
to be mediated via the AP-2 element (Hoper et al, 1997). Previous
studies reported that cAMP enhanced the transcriptional activity of
AP-2 via phosphorylation by cAMP-dependent protein kinase,
protein kinase A (Garcia et al, 1999); cAMP may release an
inhibitory protein(s), which may be constitutively associated with
AP-2 and prevent the DNA binding of AP-2 (Garcia et al, 1999).
cAMP may also promote the interaction of AP-2 with another
protein(s) to form more potent transcriptional complexes (Garcia
et al, 1999). Another study also reported that cAMP-elevating
agents enhanced DNA binding of AP-2 (Micali et al, 1996). It
should further be examined how cAMP promotes the transcrip-
tional activity of AP-2 in PMA-differentiated THP-1.
It is reported that E2 enhanced AC activity in rat uterine cells or
human breast cancer MCF-7 (Aronica et al, 1994) and also
increased cAMP content in human coronary arteries (Mugge et al,
1993) or rat duodenal cells (Picotto et al, 1996). DHT also inhibited
AC activity in rat prostate epithelia (Sutherland and Singhal, 1975)
or human scalp hair follicles (Adachi and Kano, 1970). These
previous studies support our results; however, the precise mechan-
ism for E2- or DHT-induced up- or downregulation of AC
activity is unknown. AC is mostly associated with plasma
membranes (Iyengar, 1993). The membrane receptors for certain
hormones, neurotransmitters, or other stimuli are coupled to AC
catalytic domains via guanine nucleotide-binding proteins (G-
proteins). The ligand-binding to some receptors activates AC
catalyst via stimulatory G-protein (Gs), whereas the ligand-binding
to other receptors inhibits AC catalyst activity via inhibitory G-
protein (Gi) (Iyengar, 1993). Thus there are several targets for AC
activation or inhibition; receptors, G-proteins, AC catalysts, or the
linkage between receptor and G-protein, or G-protein and AC
catalyst. The ®rst possible mechanism for steroid-induced regula-
tion of AC is that estrogen receptors positively linked to AC via Gs
may exist on membranes of PMA-differentiated THP-1 cells. In
contrast, membrane androgen receptors may be negatively linked
to AC via Gi, which is supposed in rat efferent duct epithelia
(Leung et al, 2001). Previous studies also suggested that membrane
androgen receptors may be linked to phospholipase C or Ca2+
Figure 6. The effects of signaling enzyme
activators on DHT-induced antagonism on
VEGF induction by E2. (a) PMA-differentiated
THP-1 cells were preincubated for 30 min with
or without Bt2cAMP 10
±4 M, C8 ceramide
5 3 10±6 M, or OAG 100 ng per ml, then E2
10±9 M and/or DHT 10±8 M were added to the
culture, and the cells were cultured for 24 h in
the presence or absence of the above-mentioned
agents. VEGF secretion was analyzed by ELISA.
(b) Differentiated THP-1 cells were transfected
with VEGF promoter (±856 to +54 bp)-CAT
reporter. After 24 h, the transfected cells were
preincubated with indicated agents, then
incubated with E2 and/or DHT in the presence
or absence of respective agents as above. After
18 h, VEGF promoter activity was assayed by
CAT expression of the cell lysate. The data are
shown as percent versus the values in control
cultures with medium alone, and represent the
mean 6 SEM of four separate experiments. The
control VEGF secretion and VEGF promoter
activity were the same as those in Fig 5.
*p < 0.05 versus control cultures with medium
alone, and ²p < 0.05 versus cultures with E2 alone,
by one-way analysis of variance with Scheffe's
multiple comparison test. (c) The cells were
preincubated with indicated agents, and incubated
with E2 and/or DHT as described above. After
6 h, RNA was extracted and RT-PCR products
were analyzed by electrophoresis. The data
represent four separate experiments.
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channel via G-protein (Lieberherr and Grosse, 1994). The
stimulation of AC by E2 and inhibition of AC by DHT were
not blocked by the respective nuclear receptor antagonists,
indicating that membrane receptors for E2 and DHT may be
structurally different from classical nuclear receptors (Benten et al,
1998, 1999) or post-translationally modi®ed forms of nuclear
receptors according to membrane targeting (Razandi et al, 1999).
Razandi et al (1999) reported that membrane estrogen receptor a
and b are derived from the same transcripts as those for nuclear
counterparts and are positively linked to adenylate cyclase via Gsa
subunit. In their study, ICI 182 780 did not antagonize the E2-
induced increase of cAMP, which favors our results. Several studies
also support the existence of membrane steroid receptors, some of
which are structurally mimicking (Papas et al, 1995) whereas others
are different from conventional nuclear receptors (Zheng and
Ramirez, 1999). The second possible mechanism for the steroid-
induced regulation of AC is the modi®cation of G-proteins by E2
or DHT. Gsa and Gia are active in free forms but are inactivated
by binding to G-protein bg subunits, forming heterotrimeric
complex, Gsabg or Giabg. E2 may dissociate Gsa from Gsabg or
stabilize the association of Giabg, which may lead to the increase of
active free Gsa or decrease of active free Gia, subsequently to the
enhancement of AC activation by Gsa or the suppression of AC
inhibition by Gia, respectively. DHT may act on G-proteins in a
manner opposite to that of E2. The E2-induced modulation of the
levels or of the equilibrium between associated and dissociated
states of G-protein subunits is supposed in rat liver (Yagami et al,
1994) or pituitary (Maus et al, 1989; Bouvier et al, 1991). In these
previous studies, however, the modulation of G-proteins required
Figure 7. Kinetics of the intracellular cAMP level. (a) PMA-
differentiated THP-1 cells were incubated with medium alone, E2 (10±9
M), P (10±9 M), DHT (10±8 M), or E2 plus DHT. The intracellular
cAMP level was analyzed at the indicated time points. The mean of
triplicate cultures is shown; the SD were < 10% of the means. The data
are representative of four separate experiments. (b, c) The cells were
incubated as above for 5 min. The cell lysates were analyzed for PDE
activity (c) and the particulate fractions were assayed for AC activity (b).
The data represent the mean 6 SEM of four separate experiments. *p
< 0.05 versus control values with medium alone, and ²p < 0.05 versus
values with E2 alone, by one-way analysis of variance with Scheffe's
multiple comparison test.
Figure 8. The in¯uence of 5¢-deletion on the steroid-induced up-
or downregulation of VEGF promoter activity. PMA-differentiated
THP-1 cells were transfected with CAT reporter vectors into which
various 5¢-deleted VEGF promoters were cloned. After transfection, the
cells were incubated with medium alone, E2 (10±9 M), DHT (10±8 M),
or E2 plus DHT, and CAT expression was analyzed. The data represent
the mean 6 SEM of four separate experiments. The fold increase of
CAT expression by E2 and percentage inhibition by DHT on the E2-
induced increase are depicted to the far right. *p < 0.05 versus control
values with medium alone, and ²p < 0.05 versus values with E2 alone, by
one-way analysis of variance with Scheffe's multiple comparison test.
The CAT expression in pCAT3-control vector was 141.3 6 13.5 pg
CAT per mg protein. The CAT expression by promoterless pCAT3-
basic vector was less than detectable level.
Figure 9. The in¯uence of AP-2 mutation on the steroid-induced
up- or downregulation of VEGF promoter activity. PMA-
differentiated THP-1 cells were transfected with wild-type VEGF
promoter (±88 to +54) or AP-2-mutated promoter, and were incubated
with medium alone, E2 (10±9 M), DHT (10±8 M), E2 plus SQ22536
(10±4 M), or E2 plus DHT, and CAT expression was analyzed.
Schematic representation of the wild-type and mutated ±88/±65 bp
sequence is shown at the top with the AP-2-dependent binding site
underlined and the two-nucleotide mutation indicated by bold letters.
The data represent the mean 6 SEM of four separate experiments. *p
< 0.05 versus control values with medium alone, and ²p < 0.05 versus
values with E2 alone, by one-way analysis of variance with Scheffe's
multiple comparison test.
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long-term exposure to E2, in the order of days, which may agree
with genomic effects of E2, and may not be applicable for the rapid
(= 5 min) increase of AC activity in PMA-differentiated THP-1 in
this study. Another possibility is the direct stimulation or suppres-
sion of AC catalyst activity by E2 or DHT. These steroids may
directly act on AC catalysts or modify lipid ¯uidity by binding to
membrane lipid surrounding AC catalysts and thus up- or
downregulate AC activity (Fesik and Makriyannis, 1986).
Another study also reported that E2 upregulated AC activity
indirectly by activating protein kinase C in female rat distal colon
(Doolan et al, 2000), as protein kinase C directly activates AC
catalyst type 2 or 7 by phosphorylation (Iyengar, 1993); however,
this mechanism is unlikely in this study since protein kinase C
inhibitor calphostin C did not suppress the E2-induced activation
of AC (data not shown). Further studies should elucidate the
precise mechanism for steroid-induced regulation of AC in PMA-
differentiated THP-1 cells. Although P did not alter AC activity in
PMA-differentiated THP-1, however, previous studies reported
that P inhibited AC activity in rat oocytes via membrane receptors
and the adenosine P site (Sadler and Maller, 1983). E2 inhibited AC
activity in rat heart ventricular myocytes (Li et al, 2000), which
con¯icts with our results. It appears that the steroid-induced up- or
downregulation of AC may differ with cell types (Farhat et al,
1996), possibly due to the difference in the amounts of membrane
steroid receptors or in AC isoforms or the structural difference in
membrane lipid surrounding AC.
DHT alone inhibited the constitutive AC activity and thus
reduced the intracellular cAMP level; however, it did not by itself
suppress the constitutive VEGF production in differentiated
THP-1. The ®rst possible reason for this discrepancy is that the
contribution of AP-2 to the constitutive VEGF promoter activity is
low, approximately 30%, and thus DHT-induced downregulation
of AC and resultant inhibition of the transcription via AP-2 may
not considerably disrupt the VEGF promoter activity in the absence
of cAMP-elevating agents. It appears that the constitutive VEGF
transcription may be mainly mediated by the different factor that
binds to ±88 to ±66 bp on the VEGF promoter, possibly SP-1 as
there are two SP-1 binding sites (±86 to ±80 bp and ±75 and
±67 bp) overlapping with the AP-2 element in this region (Gille
et al, 1997). The recent study also reported that constitutive VEGF
expression depended on the activity of SP-1 in human pancreatic
adenocarcinoma (Shi et al, 2001). The second possible reason is that
the constitutive transcription via AP-2 may mainly depend on
signaling molecule(s) other than protein kinase A, such as protein
kinase C (Imagawa et al, 1987), as DHT-induced decrease of cAMP
reduced the constitutive enhancer activity of AP-2 only by 30%
(Fig 10). In the presence of E2, however, cAMP level is increased,
leading to the enhancement of transcription from AP-2. Thus in
E2-stimulated cells, the transcription via AP-2 may mainly depend
on the cAMP/protein kinase A pathway, and thus DHT may
antagonize the E2-induced transcription from AP-2 by suppressing
the cAMP signal induced by E2.
In this study, the stimulatory or inhibitory effects of sex steroids
did not appear to be mediated by conventional nuclear receptors;
however, the recent study reported that E2-bound nuclear E2
receptor transactivated VEGF promoter (±2274 to +50 bp) via the
variant estrogen response element (AATCAnnnTGACT) located
1.5 kb upstream from the transcriptional start site in human
endometrial cells and uterine cancer Ishikawa cells (Mueller et al,
2000). Though this sequence is slightly different from the 13 bp
palindromic consensus estrogen response element (GGT-
CAnnnTGACC), E2-bound estrogen receptor appears to act
through such incomplete estrogen response elements (Mueller
et al, 2000). Though there are no consensus estrogen response
elements on the VEGF promoter, it contains several half-
palindromic (TGACC) estrogen response elements (Tischer et al,
1991) and it is supported that such half-palindromic motifs may
bind nuclear estrogen receptors cooperatively and confer the E2-
induced VEGF transcription in rat or human uterus (Kato et al,
1992; Cullian-Bove and Koos, 1993; Zhang et al, 1995; Shifren et al,
1996). At least in this study, however, E2-induced VEGF
transcription may not involve these elements since the region
required for E2-induced transcription (±88 to ±66) does not
contain consensus or half-palindromic estrogen response elements.
Another study also suggested that E2 may promote VEGF
transcription via transcription factor AP-1 in bovine ovarian
granulosa cells (Garrido and Saule, 1993), as E2 enhances the
synthesis of AP-1 components, c-jun and c-fos (Curran and Franza,
1988; Weisz et al, 1990). E2-bound nuclear estrogen receptor ag
also potentiates the gene transcription from AP-1 enhancer element
by binding to AP-1 complex (Paech et al, 1997). It is also suggested
that E2 may stabilize VEGF mRNA by retarding its degaradation
(Weisz and Bresciani, 1988). Thus there may be multiple
mechanisms for sex steroid-induced regulation of VEGF produc-
tion and the mechanism for the regulation may differ depending on
the cell types; VEGF transcription may be in¯uenced by the
amounts of nuclear or membrane steroid receptors, the amounts or
proportion of transcription factors like AP-2 or AP-1, or the
activity of AC. These factors may vary with cell types and/or
activation or differentiation status. The difference in experimental
conditions, such as medium types or the presence or absence of
serum, may also in¯uence the steroid-induced regulation of VEGF
production. Previous papers also reported the DHT or P-induced
enhancement of VEGF production, which is con¯icting with our
results. DHT enhanced VEGF production in human epithelial
prostatic cells (Sordello et al, 1998) and P enhanced VEGF
production in rat uterus (Cullian-Bove and Koos, 1993). These
effects of DHT and P may be mediated by genomic effects through
the respective nuclear receptors or by nongenomic effects such as
the upregulation of the signaling molecules different from AC, like
extracellular signal-regulated kinases or protein kinase C. Especially
in the cells from reproductive or sex accessory organs, like uterine,
ovary, or prostate, nuclear steroid receptors may be enriched and
the steroid-induced genomic effects through the nuclear receptors
may predominate nongenomic effects.
The incubation of differentiated THP-1 with E2 resulted in the
enhancement of VEGF-dependent growth of endothelial cells
(Fig 2). This indicates that the increase of E2 level during
pregnancy or usage of contraceptives may lead to the enhancement
of endothelial cell proliferation and subsequently to the develop-
Figure 10. The steroid-induced up- or downregulation on the
enhancer activity of AP-2. PMA-differentiated THP-1 cells were
transfected with the CAT reporter plasmid driven by AP-2 element
(p3xAP-2-tk-CAT) or enhancerless plasmid (tk-CAT), and were
incubated with medium alone, E2 (10±9 M), DHT (10±8 M), E2 plus
SQ22536 (10±4 M), or E2 plus DHT, and CAT expression was analyzed.
The data represent the mean 6 SEM of four separate experiments. *p
< 0.05 versus control values with medium alone, and ²p < 0.05 versus
values with E2 alone, by one-way analysis of variance with Scheffe's
multiple comparison test.
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ment of LCH. On the other hand, the DHT-induced antagonism
of VEGF induction by E2 indicates that DHT can be used for the
treatment of certain cases of LCH whose pathogeneses involve E2.
We should further examine the regulation of VEGF production by
sex steroids and the mechanism for the regulation in the other
stromal cells in LCH, such as ®broblasts or mast cells. Because in
LCH, pericytes are components of vessels as well as endothelial cells
(Nichols et al, 1992), we should also examine if sex steroids may
regulate the production of growth factor(s) for pericytes such as
platelet-derived growth factor.
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